Fig. 1From: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico studyEffect of the investigated drugs on the pathways that are implicated in COVID-19Back to article page